Answers are grounded in this paper and cite their sources.
A RemeGen-sponsored, randomized, open-label, multicenter phase 3 study comparing the efficacy and safety of disitamab vedotin versus treatment with the tyrosine kinase inhibitor lapatinib + capecitabine in patients with HER2-positive advanced breast cancer with liver metastasis.
No takes yet. Share an insight, caveat, or question.
Peter Hofland (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: